Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CNTO888 + doxorubicin
- Development stage
- Unknown
- Lead developer
- Janssen Biotech
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
CNTO888 + doxorubicin is a combination therapy under investigation for the treatment of advanced solid tumors. CNTO888 is a fully human IgG1κ monoclonal antibody that selectively binds and neutralizes CC-chemokine ligand 2 (CCL2), a protein implicated in tumor angiogenesis, proliferation, and metastasis. By blocking CCL2, CNTO888 aims to inhibit tumor growth and spread. Doxorubicin is an anthracycline chemotherapy agent that works primarily by intercalating into DNA and inhibiting topoisomerase II activity, leading to DNA damage and apoptosis in rapidly dividing cancer cells. This combination has been studied in early-phase clinical trials for safety and efficacy in patients with various solid tumors[6][8].
- Brand names
- AdriamycinDOXILCaelyx
- Other names
- pegylated doxorubicinliposomal doxorubicin
02
Targets
DNACCL2 (C-C motif chemokine 2)TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on CNTO888 + doxorubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CNTO888 + doxorubicin.